About Medcura
Medcura is a Healthcare company based in United States founded in 2019. Medcura has raised $87.35 million across 6 funding rounds from investors including TEDCO. Medcura offers products and services including LifeGel and Hemostasis Portfolio. Its focus areas include Life Sciences, Hematology, Medical Devices and Therapeutic. Its competitors include ExThera Medical, CytoPherx and Arteriocyte; 3 of its 3 listed competitors have raised funding.
Company details
Developer of the device for controlling bleeding. The product Triple R is used to rapidly and decisively stop bleeding after diagnostic and interventional vascular access procedures, Life Foam s a self-expanding injectable biopolymer foam to treat internal non-specific hemorrhage, LifeGel for treating bleeding from parenchymal tissue, and Rapid-Seal provides an antibacterial barrier.
- Headquarters United States
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website medcurainc.com
- Social LinkedIn X Facebook Instagram
- Total Equity Funding$87.35M (USD)
in 6 rounds
- Latest Funding Round$28.55M (USD), Series C
Apr 2025
- Investors
Products & Services of Medcura
Medcura offers a comprehensive portfolio of products and services, including LifeGel and Hemostasis Portfolio.
Flowable gel for controlling bleeding in surgical procedures
Biopolymer solutions for minimal to moderate bleeding management
Funding Insights of Medcura
Medcura has successfully raised a total of $87.35M across 6 strategic funding rounds. The most recent funding activity was a Series C round of $28.55 million completed in April 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $87.35M
- Total Rounds 6
- Last Round Series C β $28.55M
- First Round $3.02M
(Sep 2020)
- Investors Count 1
All 6 funding rounds of Medcura with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2025 | $28.55M | Series C | β | β | β |
| Apr 2024 | $22.4M | Series C | β | β | β |
| Jul 2022 | $22.49M | Series C | β | TEDCO | β |
| Nov 2021 | $3.49M | Series B | β | β | β |
| Aug 2021 | $7.4M | Series B | β | β | β |
| Sep 2020 | $3.02M | Series A | β | β | β |
1 investors in total: 1 institutional.
Investors in Medcura
Medcura has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include TEDCO.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital fund and startup accelerator programs focused on seed and early stage companies | 1998 | tedcomd.com | Columbia, United States |
Investor details for Medcura
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Medcura
16 people are tracked at Medcura (10 in leadership, 3 in board & advisors, 3 in team).
| Name | Role | Group |
|---|---|---|
Rachel Hoffman | Senior Vice President, Clinical And Regulatory Affairs / Head Of Translational Research | Leadership |
Jim Buck | President, CEO & Director | Leadership |
Matthew Dowling | Chief Scientific Officer and Director | Leadership |
Rich Vincent | CFO | Leadership |
Bruce Choi | Head of Manufacturing | Leadership |
Natasha Johnson | VP, Quality Assurance | Leadership |
Jaeho Lee | Associate Director of R&D | Leadership |
Dave Clark | Head of Strategic Partnerships | Leadership |
Steve Ford | Head of Business Development | Leadership |
Felix Vega | Director, Pre-Clinical Research | Leadership |
Ed Quilty | Director | Board & advisors |
Srinivasa Raghavan | Scientific Advisory Board Member | Board & advisors |
Larry Tiffany | Executive Chairman & Director | Board & advisors |
John Barry | SVP, Product Development & Operations | Team |
Bradon Wallace | Manufacturing Engineer | Team |
Brandon Wallace | Manufacturing Engineer | Team |
Complete people profiles for Medcura
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Medcura
3 dated milestones of Medcura across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Medcura is founded.
- Funding First funding round of $3.0M.
- Funding Latest funding round, Series C, of $28.5M.
Competitors of Medcura
Medcura has 3 listed competitors in our database, 3 of them funded. They include ExThera Medical, CytoPherx and Arteriocyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| extheramedical.com | 2007 | Berkeley, United States | $54.59M | 23 | Medical devices for the rapid treatment of bloodstream infections and pathogen-reduction in blood banking | |
| cytopherx.com | 1994 | Ann Arbor, United States | $45.69M | Cytopheresis systems for inflammatory conditions | ||
| arteriocyte.com | 2007 | Hopkinton, United States | $15.11M | 7 | Devices to facilitate blood component and bone marrow transplant |
Detailed competitors of Medcura
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Medcura
The website of Medcura (medcurainc.com) receives about 3.1K visits a month.
- Monthly visits3.1K
▼ 17.5% vs previous month
Websites whose visitors overlap most with Medcura. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
undifferentiatedmedicalstudent.com | undifferentiatedmedicalstudent.com | 100% | #3,453,786 | β |
Top companies in Hematology
3 companies that operate in the same segment as Medcura (Hematology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Catheter-based thrombectomy devices for vascular emboli removal are developed. | 2011 | Irvine, California, United States | USD 51.89 M | USD 493.63 M | 696 | |
Small molecules are developed to treat hematologic and musculoskeletal disorders. | 2016 | Lexington, Kentucky, United States | USD 90 M | USD 244.06 M | 169 | |
Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders | 2016 | Menlo Park, California, United States | USD 300 M | 384 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Medcura
Complete news archive for Medcura
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Medcura
Medcura was founded in 2019 and raised its 1st funding round 1 year after it was founded.
Medcura is headquartered in United States.
Medcura is a funded company, having raised a total of $87.35M across 6 funding rounds to date. The company's 1st funding round was a Series A of $3.02M, raised on Sep 2020.
Developer of the device for controlling bleeding. The product Triple R is used to rapidly and decisively stop bleeding after diagnostic and interventional vascular access procedures, Life Foam s a self-expanding injectable biopolymer foam to treat internal non-specific hemorrhage, LifeGel for treating bleeding from parenchymal tissue, and Rapid-Seal provides an antibacterial barrier.
Medcura's top competitors include ExThera Medical, Arteriocyte and CytoPherx.
Medcura offers LifeGel and Hemostasis Portfolio.
Medcura has 1 investor. Key investors include TEDCO.

